IGF1 and neoplasm: The reasoning underlying this hypothesis is that tumours that develop in a patient with high IGF bioactivity are more likely to become dependent on (or even ‘addicted’ to) IGF-1 receptor signalling, and therefore may be more sensitive to F therapy.